ClinicalTrials.gg
Not yet recruitingNCT07782294Updated Aug 24, 2026

AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis

An observational study in Gastric Cancer, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
542
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,183 studies in Stomach Neoplasms with a site in China — 480 open to participants now, 556 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
104th of 303
542 · median 300
Started
2026
with 91 others
Observational
303 of 1,183
132 open now
Primary completion
2027-12
later than 424 of 555 live
Registered
1,153rd of 1,183
by date

Among the 1,183 studies in Stomach Neoplasms with a site in China, this one is the 104th largest by planned enrollment of the 303 observational ones that give a count, is one of 92 that started in 2026, is one of 303 observational ones, reaches primary completion later than 424 of the 555 other live ones, and was the 1,153rd registered.

Stomach Neoplasms

3,401 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

480 of the 1,183 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

475 more — sign in →

All 480 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,183 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to prospectively validate the diagnostic performance of an rbcDNA-based assay for gastric cancer detection in individuals undergoing upper gastrointestinal endoscopy. The study aims to evaluate the diagnostic accuracy of rbcDNA in distinguishing newly diagnosed, treatment-naïve gastric cancer from non-cancerous gastric conditions, using endoscopic and histopathological findings as the reference standard. The study will also compare the diagnostic performance of the rbcDNA-based approach with currently available clinical biomarkers, including serum tumor markers, Helicobacter pylori testing, and pepsinogen-related indices.

All enrolled participants will provide a 2 mL peripheral blood sample for rbcDNA analysis.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • Gastric cancer
  • rbcDNA
  • Early detection
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants consist of patients with gastric diseases undergoing gastroscopy, enrolled from three different medical centers across China.

Eligibility criteria

Inclusion Criteria

  • Age between 18 and 75 years.
  • Scheduled for upper gastrointestinal endoscopy for the assessment of gastric diseases, including gastric cancer (stage I-IV), gastric precancerous lesions, and other benign gastric disorders.
  • No previous treatment for the current gastric disease prior to blood collection, including surgery, chemotherapy, radiotherapy, immunotherapy and other anti-tumor therapies.
  • Able and willing to participate and provide written . Exclusion Criteria
  • Receiving therapeutic gastroscopy or endoscopic resection for gastric lesions diagnosed in other institutions.
  • Presence of conditions that hinder complete gastric endoscopic visualization and reliable lesion evaluation, such as gastric retention and severe esophageal stenosis.
  • History of other malignant tumors, prior anti-tumor treatment, or partial/total gastrectomy.
  • Severe hemodynamic instability, malignant arrhythmia, unstable cardiovascular diseases, or recent major surgery.
  • Hematological disorders, recent blood transfusion history, severe active infection, chronic infectious diseases (e.g., ), or severe systemic inflammation affecting blood cell composition.
  • Pregnant or breastfeeding women.
  • Enrolled in other concurrent clinical trials that may affect the current study results.
  • Refusal to sign informed consent or failure to comply with study procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
542 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • GC group

    Subjects with histopathologically confirmed gastric cancer (stage I-IV)

  • Contol group

    Non-gastric cancer subjects, including superficial gastritis, gastric ulcer, adenomatous gastric polyps, atrophic gastritis, intestinal metaplasia, etc.

06

What researchers measure

Primary outcomes

  1. Sensitivity of the rbcDNA blood test for gastric cancer screening

    Sensitivity is defined as the percentage of participants with pathologically confirmed gastric cancer who have a positive rbcDNA test result. Final pathological diagnosis from standard hospital clinical examination serves as the gold-standard reference for calculation. Higher sensitivity indicates fewer true gastric cancer cases are missed by the test.

    Time frame: Through study completion, an average of 1 year

  2. Specificity of the rbcDNA blood test for gastric cancer screening

    Specificity is defined as the percentage of participants without gastric cancer (with other benign gastric disorders) who have a negative rbcDNA test result. Final pathological diagnosis from standard hospital clinical examination serves as the gold-standard reference for calculation. Higher specificity indicates fewer false-positive test results.

    Time frame: Through study completion, an average of 1 year

  3. Overall accuracy of the rbcDNA blood test for gastric cancer screening

    Overall accuracy is defined as the percentage of all enrolled participants whose rbcDNA test result matches the final clinical-pathological gastric disease diagnosis. Final pathological diagnosis from standard hospital clinical examination serves as the gold-standard reference for calculation.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Sensitivity of conventional gastric cancer screening tests

    Percent of pathologically-confirmed gastric cancer participants with positive results from conventional screening assays, including serum tumor markers, Helicobacter pylori testing and pepsin-related indices. Calculated against final pathological gastric cancer diagnosis as unified gold standard.

    Time frame: Through study completion, an average of 1 year

  2. Specificity of conventional clinical gastric cancer screening tests

    Percent of participants without pathologically-confirmed gastric cancer with negative results from conventional screening assays, including serum tumor markers, Helicobacter pylori testing and pepsin-related indices. Calculated against final pathological gastric cancer diagnosis as unified gold standard.

    Time frame: Through study completion, an average of 1 year

  3. Overall accuracy of conventional clinical gastric cancer screening tests

    Proportion of all participants with consistent results from conventional screening assays relative to final pathological gastric cancer diagnosis (unified gold-standard reference). Conventional assays include serum tumor markers, Helicobacter pylori testing and pepsin-related indices.

    Time frame: Through study completion, an average of 1 year

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared publicly due to intellectual property protection of rbcDNA detection technology, restrictions from institutional ethics and informed consent of participants.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

Of 323 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 15 months is below that.

Counting every sponsor, half of 365 studies reached it within 54 months; a quarter within 29 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 24, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07782294
Collaborators
Anyang Tumor Hospital, RenJi Hospital
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 24, 2026

Study contacts

Yuehua Han
Contact
13858126927@163.com
+86 13858126927
Yuehua Han
study chair · Second Affiliated Hospital, Zhejiang University, School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion